SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as speculation mounts around its potential integration into X (formerly Twitter) for payments, driven by its enduring association with Elon Musk. The community is actively discussing possible price rallies and whether this marks the beginning of a broader meme coin season, alongside a vocal group of skeptical investors.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is trending as the crypto community buzzes about a potential 'frog cycle' and renewed meme coin season, with supporters anticipating significant upward movement while skeptics warn of its speculative nature and high volatility.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

ICP is generating buzz amidst discussions surrounding its "Mission 70" tokenomics to reduce inflation and recent national subnet initiatives for digital sovereignty, notably with Switzerland and Pakistan. The community remains passionately split between those confident in its foundational technology for decentralized cloud and others questioning its market performance despite ongoing ecosystem growth and real-world adoption use cases.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending amid community reactions to Trezor's rejection of MWEB privacy integration, sparking debate on coin custody. Despite its perceived underperformance, many analysts highlight bullish technicals and deep undervaluation, fueling anticipation for a significant price recovery.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending as community members debate whether the "crypto winter" is over, fueling hopes for an "altcoin season" among meme coins. Despite strong skepticism from some, many holders are actively discussing whale accumulation and the potential for SHIB to rebound from current levels.

Pop Cat refers to a series of videos in which using an image of a cat named Oatmeal, the cat is photoshopped as if it's opening its mouth wide in an O shape.

Popcat

POPCAT is generating significant conversation, fueled by its addition to major exchanges and the broader 'cat coin supercycle' narrative. The community is sharply divided, with many actively accumulating on dips and anticipating substantial growth, while others express concern over rapid price drops and question its market resilience.

Arbor Realty Trust, Inc. operates as a real estate investment trust, which engages in the provision of loan origination and servicing for multifamily, seniors housing, healthcare, and diverse commercial real estate assets. It operates through the Structured Business and Agency Business segments. The Structured Business segment offers a diversified portfolio of structured finance assets in the multifamily, single-family rental, and commercial real estate markets. The Agency Business segment focuses on the sale and service of a range of multifamily finance products through the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation. The company was founded by Ivan Kaufman in June 2003 and is headquartered in Uniondale, NY.

Arbor Realty Trust Inc.

ABR is trending as significant insider buying by management at depressed stock levels fuels community speculation of a potential short squeeze amid high short interest. Investors are keenly focused on the company's dividend sustainability ahead of upcoming earnings, with broader optimism for the REIT sector driven by anticipated interest rate cuts and falling Treasury yields.

Roundhill ETF Trust - Roundhill HOOD WeeklyPay ETF

Roundhill Hood WeeklyPay ETF

Roundhill Hood WeeklyPay ETF ($HOOW) is a hot topic, with investors keen on its weekly dividends ahead of Robinhood ($HOOD) earnings and recent bullish analyst targets driving speculation. While some view $HOOW as a 'cash cow' tied to $HOOD's expected recovery, others voice caution regarding its leveraged structure and historical sensitivity to market downturns, sparking debate about its long-term recovery potential.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE is trending following its new listing on MEXC Meme+, energizing its dedicated community. Enthusiastic holders are actively discussing its unique origin as Grok's AI dog, deflationary tokenomics, and perceived stability, positioning it as a resilient player in the AI memecoin space.

Kinross Gold Corp. engages in the production, acquisition, exploration, and development of gold properties. The firm operates through the following business segments: Tasiast, Paracatu, La Coipa, Fort Knox, Round Mountain, Bald Mountain, and Corporate & Other. The Fort Knox segment includes Fort Knox and Manh Choh mine. Its mining operations are in the United States, Brazil, Chile, Mauritania, and Canada. The company was founded by Robert MacKay Buchan on May 31, 1993 and is headquartered in Toronto, Canada.

Kinross Gold Corp.

Kinross Gold is a top trending "best in breed" gold miner, bolstered by surging gold prices and robust earnings beats that have consistently exceeded expectations. The community highlights its strong cash flow and ongoing organic growth projects as key drivers, viewing KGC as a stable safe-haven asset amid broader market uncertainties and anticipating continued upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been given a consensus recommendation of "Hold" by the seventeen analysts that are presently covering the company, Marketbeat...

Hims & Hers Health (NYSE:HIMS) Hits New 52-Week Low - Here's Why

Hims & Hers Health (NYSE:HIMS) Sets New 1-Year Low - Here's Why...

Hims & Hers Strengthens Integrated Personalized Digital Care Platform

HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.

Novo CEO blasts 'mass compounding' of GLP-1 drugs as safety battle escalates

GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety.'When you go and try to source raw materials...

HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?

Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.

<ul class="summary-bullets"><li>The three-day rout was driven by Novo Nordisk’s lawsuit and an FDA crackdown on compounded GLP-1 drugs.</li><li>Deutsche Bank and Canaccord cut price targets on HIMS but pointed to 70%–80% upside from current levels.</li><li>Canaccord said the selloff has already stripped out much of the value tied to compounded semaglutide sales.&nbsp;</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) are drawing renewed scrutiny after a brutal three-day selloff tied to regulatory pressure and legal action around compounded GLP-1 drugs, with at least one Wall Street firm arguing that much of the downside risk may now be reflected in the stock.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> fell 11% on Tuesday, extending its losing streak to an eighth straight session, as the FDA crackdown and Novo Nordisk’s lawsuit accelerated an already ongoing selloff.&nbsp;<h2 class="st-heading-2">Wall Street Sees Legal Risk Largely Priced In</h2>Deutsche Bank lowered the price target on Hims &amp; Hers to $31 from $42, implying an upside of about 80% from the stock’s last close, while reiterating a ‘Hold’ rating. The brokerage said Hims is “under siege” following the abrupt reversal of its GLP-1 pill launch.Canaccord was slightly more optimistic. The firm lowered its price target to $30 from $68, implying roughly 74% upside from current levels, while maintaining a ‘Buy’ rating. Canaccord said Novo Nordisk’s lawsuit adds “another layer of operational uncertainty,” but argued that the three-day share selloff has “implicitly removed” most of the value tied to compounded semaglutide sales. As a result, the firm believes a significant portion of the legal risk may already be priced into the stock.<h2 class="st-heading-2">FDA Crackdown And Novo Lawsuit Hit Hims GLP-1 Push</h2>Novo Nordisk said on Monday it has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">filed a lawsuit</a> seeking a permanent ban on Hims’ sales of compounded semaglutide products, alleging patent infringement and unlawful mass marketing of unapproved versions of Wegovy and Ozempic.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold-standard review process,” said Novo Nordisk senior vice president and general counsel John F. Kuckelman, calling the practice “dangerous and deceptive.”The legal action followed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-volatility-retail-bulls-vs-bears-after-pill-halt/cZbHmsDR48g">warning</a> from the U.S. Food and Drug Administration, which said it would crack down on GLP-1 active pharmaceutical ingredients used in non-approved compounded drugs. The FDA said it may restrict access to such ingredients and refer violations to the Department of Justice, citing safety and quality concerns.In response, Hims said it would stop offering its $49 compounded semaglutide pill just days after launching the product, saying it had held “constructive conversations” with industry stakeholders.<h2 class="st-heading-2">Wall Street View On HIMS Downside Scenarios</h2>Earlier this week, Citi cut its price target on Hims &amp; Hers to $16.50 from $30 and maintained a ‘Sell’ rating, warning that the company’s GLP-1 strategy was “risky and aggressive.” Citi said its target reflects a 25% probability of Hims losing all weight-loss drug sales, a 60% base-case scenario of losing half of those sales, and only a 15% bull-case outcome with limited GLP-1 downside.Bank of America Securities also trimmed its target to $21 from $26 and reiterated an ‘Underperform’ rating. The firm noted that the FDA did not distinguish between oral and injectable GLP-1 products in its warning, raising the risk that regulatory scrutiny could extend to Hims’ injectable semaglutide offerings.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for HIMS was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_1f0284a84d.webp" alt="hims ss.png" width="968" height="143"><figcaption>HIMS sentiment and message volume as of February 11 | Source: Stocktwits</figcaption></figure>One user said, “may be it will take couple of years to go $60 again . It did 5 times last year but this time its different. This needs time.”<stembedurl>https://stocktwits.com/nostoplosss/message/644639747</stembedurl>Another user said that, with earnings approaching on Feb. 23, the stock could see a rebound. They added that “stock is already on lowest bottom u can imagine , load the boat before its too late”<stembedurl>https://stocktwits.com/expato14/message/644637544</stembedurl>HIMS stock has declined 61% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In?

Deutsche Bank and Canaccord cut price targets on HIMS but pointed to 70%-80% upside from current levels.

Equity

<ul class="summary-bullets"><li>GDNF outperformed semaglutide, the active ingredient in Wegovy and Ozempic, across several key measures, Hoth said.</li><li>The 12-week study showed that female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, whereas semaglutide showed no meaningful effect.</li><li>The company said GDNF reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease.</li></ul>Hoth Therapeutics (HOTH), on Tuesday, announced preclinical results from a Veterans Administration-backed study evaluating glial cell-derived neurotrophic factor (GDNF) as a potential treatment for obesity and metabolic-associated steatotic liver disease (MASLD).The company stated that in a head-to-head comparison, GDNF outperformed semaglutide, the active ingredient in weight-loss drugs such as Wegovy and Ozempic, across several key measures, including weight control, glucose tolerance, liver weight reduction, and adipose tissue control.<a href="https://stocktwits.com/symbol/HOTH">HOTH shares</a> were up over 5% in pre-market trading but reversed gains after the opening bell, trading 6% lower.<h2 class="st-heading-2">What Did The 12-Week Study Show?</h2>During the 12-week study, female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, eventually entering a stabilization phase, whereas semaglutide showed no meaningful effect. Researchers noted that higher doses or longer durations could amplify GDNF’s effects.GDNF also normalized fasting glucose levels and improved responses to glucose challenges. Additionally, the therapy reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease, a common issue with obesity.“These results are a monumental step forward for Hoth and the fight against obesity. GDNF not only matched but exceeded semaglutide in critical areas, opening doors to a new era of safer, more effective therapies,” said Robb Knie, CEO of Hoth Therapeutics.<h2 class="st-heading-2">What’s Next?</h2>Hoth plans additional studies on liver pathology, lipid content, and gene and protein expression to better understand GDNF’s mechanism, with clinical trials targeted for 2027.Weight-loss drugs have become a central focus for the pharmaceutical industry, driving revenue growth for leaders like Eli Lilly and Novo Nordisk as other companies race to enter the booming market.The segment has been under regulatory spotlight in the aftermath of Hims &amp; Hers launching a compounded version of Wegovy last week, which the company has since withdrawn following legal notices from NOVO and the U.S. Food and Drug Administration.&nbsp;&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment turned ‘bullish’ from ‘neutral’ a day earlier, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/HOTH_jpg_40deb046fb.webp" alt="HOTH.jpg">One user called for patience amid the intraday decline.<stembedurl>https://stocktwits.com/Tom678/message/644546402</stembedurl>HOTH shares are down around 21% so far this year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/why-did-azi-stock-reverse-gains-in-premarket/cZbUIHFR4Yy">AZI Stock Reverses Early Gains To Slump 30% In Pre-Market – What Happened?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide

NVO shares jump 3.6% after Hims & Hers halts compounded semaglutide following an FDA warning and patent lawsuit.

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit

Hims & Hers Health (NYSE:HIMS), a direct-to-consumer telehealth platform, closed Monday at $19.33, down 16.03%. The stock dropped as news of a lawsuit from Novo Nordisk (NYSE:NVO) came on top of...

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.33, denoting a -16.05% move from the preceding trading day.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Stocktwits

Stocktwits Polls

Hims & Hers Health Inc

With a significant short interest around 41% of the float, many anticipate a massive short squeeze, fueling intense debates between optimistic bulls and persistent bears.

Traders are keenly following the legal battle with Novo Nordisk over GLP-1 medications, debating HIMS's "disruptor" status against "piracy" claims and potential FDA actions.

Amidst recent price drops and legal uncertainties, investors are re-evaluating HIMS's fair value, weighing its customer base, new markets like Canada, and diversified services against current market sentiment.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.04	--	--	N/A
Q3 '25	$0.09	$0.06	-36.40%	MISSED
Q2 '25	$0.15	$0.17	12.73%	BEAT
Q1 '25	$0.12	$0.20	65.41%	BEAT
Q4 '24	$0.11	$0.11	1.53%	BEAT

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest HIMS News

HIMSHims & Hers Health Inc